Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome

Neurology

Prevalence

0.1 / 100K

0 drugs in development·0 companies·1 clinical trial

Frequently asked questions

How many clinical trials target Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome?

There are 1 clinical trial targeting Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome tracked by BioSniper.

What is the prevalence of Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome?

The estimated prevalence of Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome is approximately 0.1 per 100,000 population.

Deep-dive into Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome — Drugs in Development & Clinical Trials | BioSniper